Clinical efficacy of atezolizumab plus bevacizumab for first-line treatment of unresectable hepatocellular carcinoma
10.3760/cma.j.cn115610-20210629-00318
- VernacularTitle:阿替利珠单克隆抗体联合贝伐珠单克隆抗体一线治疗不可切除肝细胞癌的临床疗效
- Author:
Xiaoyun HU
1
;
Mengya ZANG
;
Qi LI
;
Guosheng YUAN
;
Rong LI
;
Jinzhang CHEN
Author Information
1. 器官衰竭防治国家重点实验室 广东省病毒性肝炎研究重点实验室 南方医科大学南方医院感染内科 南方医科大学南方医院肝脏肿瘤中心，广州 510515
- Keywords:
Liver neoplasms;
Primary;
Immunotherapy;
Targeted therapy;
Atezoli-zumab;
Bevacizumab;
Clinical efficacy;
Safety
- From:Chinese Journal of Digestive Surgery
2021;20(S2):20-24
- CountryChina
- Language:Chinese
-
Abstract:
Advanced hepatocellular carcinoma (HCC) has limited treatment options and poor prognosis. Only two tyrosine kinase inhibitors have been approved as single agents for first-line treatment over the last decade. In 2020, atezolizumab combined with bevacizumab was appro-ved for first-line treatment of advanced HCC. As the first brand-new therapy to surpass sorafenib, atezolizumab combined with bevacizumab showed good safety and life quality in patients. The authors introduced the diagnosis and treatment of a China Liver Cancer Staging Ⅲb HCC patient receiving atezolizumab combined with bevacizumab, in order to provide references for patient management.
